[Federal Register Volume 79, Number 14 (Wednesday, January 22, 2014)]
[Notices]
[Pages 3627-3628]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-01158]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances, Notice of Application:
Noramco, Inc.
Pursuant to 21 CFR 1301.33(a), this is notice that on August 5,
2013, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware
19801-4417, made application by renewal to the Drug Enforcement
Administration (DEA) as a bulk manufacturer of the following basic
classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Codeine-N-oxide (9053)..................... I
Dihydromorphine (9145)..................... I
Morphine-N-oxide (9307).................... I
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Phenylacetone (8501)....................... II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Morphine (9300)............................ II
Oripavine (9330)........................... II
Thebaine (9333)............................ II
Opium extracts (9610)...................... II
Opium fluid extract (9620)................. II
Opium tincture (9630)...................... II
Opium, powdered (9639)..................... II
Opium, granulated (9640)................... II
Oxymorphone (9652)......................... II
Noroxymorphone (9668)...................... II
Tapentadol (9780).......................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement
[[Page 3628]]
Administration, Office of Diversion Control, Federal Register
Representative (ODW), 8701 Morrissette Drive, Springfield, Virginia
22152; and must be filed no later than March 24, 2014.
Dated: January 14, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2014-01158 Filed 1-21-14; 8:45 am]
BILLING CODE 4410-09-P